Welcome to our dedicated page for Lifevantage news (Ticker: LFVN), a resource for investors and traders seeking the latest updates and insights on Lifevantage stock.
LifeVantage Corporation (Nasdaq: LFVN) is a health and wellness company centered on nutrigenomics and cellular activation, and its news flow reflects this focus. The company regularly issues updates on its activator-based product portfolio, consultant community, scientific research, and participation in investor and industry events. As the Activation company, LifeVantage highlights how its products, such as the Protandim family, TrueScience Liquid Collagen, the MindBody GLP-1 System, and the comprehensive gut activator P84, fit into broader wellness systems and scientific narratives.
News about LifeVantage often covers new product launches and enhancements, including additions to its activation-supporting nutrients, AXIO nootropic energy drink mixes, and TrueScience skin and hair care line. Company communications also describe major field events like Momentum Academy and Global Kickoff, where Consultants receive training, hear about new tools, and learn strategies related to enrollment, retention, and advancement. These events frequently coincide with the introduction of new offerings or the integration of acquired product lines such as LoveBiome’s P84.
Investors following LFVN can also expect announcements on quarterly and annual financial results, dividend declarations, share repurchase activity, and guidance ranges, as well as notices of participation in conferences and fireside chats. The company’s releases include commentary from management on strategic initiatives such as integrating LoveBiome assets, expanding its wellness ecosystem, and advancing digital capabilities like the Daily Activation app.
This news page aggregates these updates so readers can track developments in LifeVantage’s product science, consultant network, and corporate strategy in one place. For anyone monitoring LFVN stock, the consultant-driven business model, or trends in nutrigenomics-focused wellness products, the news feed provides an ongoing view of how the company communicates its progress and priorities.
LifeVantage (Nasdaq: LFVN) held a virtual Global Kickoff on January 12, 2026, themed “Breakthrough,” uniting consultants worldwide and highlighting the LoveBiome integration.
Key announcements: launch of the Daily Activation mobile app for consultants and customers; the Activate90 Challenge running 12 weeks from the week of January 12 through April; and progress on the Healthy Edge wellness system.
Company-cited third-party in vitro data reported Healthy Edge activated 358 unique genes and a subset of 29 genes linked to cellular adaptability and stress resilience. Additional product rollouts are planned in 2026.
LifeVantage (Nasdaq: LFVN) announced on January 7, 2026 the appointment of Mike Edwards as Chief Technology Officer to lead the company’s digital transformation. Edwards brings more than 25 years of technology leadership with experience in eCommerce, artificial intelligence, CRM systems, mobile applications, and scaling global eCommerce infrastructure. The company said Edwards will focus on accelerating digital initiatives to streamline operations, enhance customer and Consultant experiences, and support global growth.
LifeVantage (Nasdaq: LFVN) will participate in the 28th Annual ICR Conference in Orlando, FL, January 12-14, 2026. CEO Steve Fife and CFO Carl Aure will present at approximately 1:00 p.m. ET on Monday, January 12, 2026. A live webcast of the presentation will be available on the company's Investor Relations News & Events page.
This provides investors and analysts access to company leadership commentary and a webcast replay option for those unable to attend live.
LifeVantage (Nasdaq: LFVN) announced that CEO Steve Fife and CFO Carl Aure will participate in a Water Tower Fireside Chat on Thursday, December 11, 2025. The live webcast will begin at approximately 2:00 p.m. ET and is open to all investors. Interested parties can register via the company's Investor Relations events page or the provided registration link.
This presentation offers investors a direct opportunity to hear management commentary and updates in a live Q&A-style format.
LifeVantage (Nasdaq: LFVN) announced in vitro results for its proprietary P84 formula on Nov 12, 2025 showing biologically meaningful effects on 14 gut peptides and proteins linked to regulation, repair, and restoration.
Key measured changes included GRP +1,087%, TFF3 +116%, VIP +100%, OXM +77%, and CCK +69%. The study used four gut cell types and reported that P84 exceeded typical biomarker thresholds (20–30%) across multiple targets. LifeVantage said it acquired LoveBiome assets in October 2025 and will next perform mRNA sequencing combining P84 with Protandim Nrf2 Synergizer and MindBody GLP-1 System.
LifeVantage (Nasdaq:LFVN) announced that its Board of Directors approved a quarterly cash dividend of $0.045 per share. The dividend will be paid on December 15, 2025 to shareholders of record at the close of business on December 1, 2025. This is a declared cash distribution to common stockholders approved by the company’s board.
LifeVantage (Nasdaq: LFVN) reported Q1 fiscal 2026 results for the quarter ended Sept 30, 2025, with revenue $47.6M (+0.7% YoY; +0.3% ex-FX). Gross profit was $37.8M (79.5% of revenue). Net income was $2.2M or $0.17 diluted; adjusted EPS was $0.18. Adjusted EBITDA was $3.9M. Cash and equivalents were $13.1M at Sept 30, 2025; no debt outstanding. The company closed the strategic acquisition of LoveBiome and repurchased 44,000 shares for ~$0.6M. A cash dividend of $0.045 per share was declared, payable Dec 15, 2025. Fiscal 2026 guidance reiterated: revenue $225–240M, adjusted EBITDA $23–26M, adjusted EPS $1.00–1.15.
LifeVantage (Nasdaq: LFVN) concluded Momentum Academy 2025 in Dallas on Oct 23–25, 2025, bringing together thousands of Consultants to deliver new products, tools, and business strategies under the theme “Love Life & Drive.”
The event marked the first large in-person integration of LoveBiome Consultants after the companies began combining on Oct 1, 2025. Attendees trained on product pairing Protandim Nrf2 Synergizer with LoveBiome P84, and saw launches including LoveBiome P84 purchasable via LifeVantage, TrueScience Charcoal Refining Mask, and an updated AXIO Green Apple flavor.
LifeVantage (NASDAQ:LFVN) will release financial results for its fiscal first quarter ended September 30, 2025 after market close on Tuesday, November 4, 2025.
The company will hold an investor conference call on November 4, 2025 at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time). U.S. dial-in: (877) 704-4453; international dial-in: (201) 389-0920. A telephone replay will be available about two hours after the call through Tuesday, November 18, 2025 via U.S. replay (844) 512-2921 or international replay (412) 317-6671 using confirmation code 13756552.
A simultaneous live webcast will be available on the Investor Relations site at https://lifevantage.gcs-web.com/events-and-presentations or directly at the provided webcast link; the webcast archive will remain available for approximately 30 days.
LifeVantage (Nasdaq: LFVN) announced that Steve Fife, President and Chief Executive Officer, will participate in the LD Micro Main Event XIX in San Diego, October 19-21, 2025.
Mr. Fife will meet with investors and present at approximately 5:30 p.m. Eastern Time on Monday, October 20, 2025. A live webcast will be available on the company’s Investor Relations News & Events page at https://lifevantage.gcs-web.com, and a replay will be archived on the company website.
FAQ
What is the current stock price of Lifevantage (LFVN)?
What is the market cap of Lifevantage (LFVN)?
